No Prescription |
 |
 | ||
|
Tiberal Generic Ornidazole |
|
| ||
No Prescription » Prescription Drugs 16 » Tiberal Generic Ornidazole Indications and Usage1.Bacterial vaginosis (non-specific vaginitis). 2.Trichomoniasis. Genitourinary infections in women and men due to Trichomonas vaginalis. 3.Amoebiasis. All intestinal infections due to Entamoeba histolytica including amoebic dysentery. All extraintestinal forms of amoebiasis especially amoebic liver abscess. Giardiasis (lambliasis). 4.Infections due to anaerobic bacteria. Treatment of infections such as septicaemia meningitis peritonitis postoperative wound infections puerperal sepsis septic abortion and endometritis with demonstrated or suspected involvement of susceptible bacteria (see Properties and Effects). 6.Prophylaxis during surgical interventions particularly those involving the colon and in gynaecological operations. Dosage and AdministrationStandard DosageThe tablets must always be taken after meals.TrichomoniasisThere are two possible therapeutic regimens: Single-dose therapy (for acute trichomoniasis); five-day therapy (for chronic forms of trichomoniasis). The tablets should be taken after meals.(a) Single dose therapy(b) Five day therapyType of Treatment Daily Dosage(500 mg tablets) (a) Single-dose 3 tablets in the evening (b) Five-day therapy 2 tablets (1 tablet mornings and evenings) In all cases the sexual partner should also be treated using the same oral dosage so as to avoid reinfection.The dosage for children is 25 mg per kg bodyweight per day given in a single dose.Amoebiasis(a) Three-day treatment of patients with amoebic dysentery(b) Five-to-ten-day treatment for all forms of amoebiasisDuration of Treatment Daily Dosage Adults and children over 35 kg Children up to 35 kg a) Three days 3 tablets in one evening doseOver 60 kg bodyweight:4 tablets ( 2 tablets mornings and evenings) 125 mg (1/4 tablet) per 3 kg bodyweight in one dose(equivalent to 40 mg per kg) b) Five to ten days 2 tablets (1 tablet mornings and evenings) 125 mg (1/4 tablet) per 5 kg bodyweight in one dose (equivalent to 25 mg per kg) Giardiasis (lambliasis)Duration of Treatment Daily dosage Adults and children over 35 kg Children up to 35 kg One to two days 3 tablets in the evening in one dose 125 mg (1/4 tablet) per 3 kg bodyweight in one dose(equivalent to 40 mg per kg) Anaerobic InfectionsProphylaxis: 1500 mg orally 12 hours before surgery then 500 mg 12-hourly for 3 to 5 days postoperatively. Buy Tiberal Generic Ornidazole and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Tiberal Generic Ornidazole: Product Type: Prescription Drugs 16 Tiberal ( Generic Ornidazole ) Tiberal (Generic Ornidazole) Generic Ornidazole 500mg Generic Ornidazole Tiberal
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
